Najat Khan
CEO, President at Recursion Pharmaceuticals, Inc. (RXRX); Chief R&D Commercial Officer at Recursion Pharmaceuticals, Inc. (RXRX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $807K
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 10SEC | RXRXRecursion Pharmaceuticals, Inc. | Sell Plan | 22,4082,072,890 held (−1%) | $3.52 | $79K | -1.6% |
| Jun 5SEC | RXRXRecursion Pharmaceuticals, Inc. | Sell Plan | 23,5882,175,796 held (−1%) | $3.58 | $84K | -3.2% |
| Mar 11SEC | RXRXRecursion Pharmaceuticals, Inc. | Sell Plan | 28,2982,262,085 held (−1%) | $3.35 | $95K | +3.4% |
| Dec 29SEC | RXRXRecursion Pharmaceuticals, Inc. | Sell Plan | 124,403611,135 held (−17%) | $4.41 | $549K | -21.4% |
- Sell
CEO, President Najat Khan sold $79K of RXRX at $3.52 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Najat Khan sold $84K of RXRX at $3.58 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO, President Najat Khan sold $95K of RXRX at $3.35 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief R&D Commercial Officer Najat Khan sold $549K of RXRX at $4.41 — pre-scheduled 10b5-1 plan sale.